Citigroup Inc Begins Coverage on Grifols SA, Barcelona (GRFS)

Citigroup Inc began coverage on shares of Grifols SA, Barcelona (NASDAQ:GRFS) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating on the biotechnology company’s stock.

Several other research analysts have also recently commented on GRFS. Bank of America Corporation reissued a buy rating on shares of Grifols SA, Barcelona in a research note on Tuesday, July 4th. Zacks Investment Research raised Grifols SA, Barcelona from a hold rating to a buy rating and set a $24.00 target price for the company in a research note on Tuesday, July 4th. Finally, BidaskClub cut Grifols SA, Barcelona from a hold rating to a sell rating in a research note on Wednesday, July 5th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. Grifols SA, Barcelona currently has a consensus rating of Hold and a consensus price target of $24.00.

Grifols SA, Barcelona (GRFS) traded up $0.69 on Tuesday, reaching $23.89. The company had a trading volume of 1,249,145 shares, compared to its average volume of 588,909. The stock has a market capitalization of $15.87 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.70 and a beta of 1.07. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.39 and a current ratio of 3.17.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.com-unik.info/2017/11/03/citigroup-inc-begins-coverage-on-grifols-sa-barcelona-grfs.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Advisory Services Network LLC grew its stake in Grifols SA, Barcelona by 26.2% during the 2nd quarter. Advisory Services Network LLC now owns 9,564 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 1,987 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Grifols SA, Barcelona during the 2nd quarter worth about $223,000. Stifel Financial Corp boosted its position in shares of Grifols SA, Barcelona by 4.3% during the 1st quarter. Stifel Financial Corp now owns 11,630 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 476 shares in the last quarter. Stevens Capital Management LP acquired a new position in shares of Grifols SA, Barcelona during the 2nd quarter worth about $236,000. Finally, Advisor Group Inc. boosted its position in shares of Grifols SA, Barcelona by 2.8% during the 2nd quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 309 shares in the last quarter. 21.93% of the stock is owned by hedge funds and other institutional investors.

Grifols SA, Barcelona Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Analyst Recommendations for Grifols SA, Barcelona (NASDAQ:GRFS)

What are top analysts saying about Grifols SA Barcelona? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols SA Barcelona and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit